Published in J Clin Oncol on May 01, 2003
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol (2009) 1.49
Overview of prostate-specific membrane antigen. Rev Urol (2004) 1.34
Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology (2011) 1.30
Prostate-specific membrane antigen-based imaging. Urol Oncol (2012) 1.22
Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges. Cancer Res Treat (2010) 0.92
Management of biochemical recurrence after primary localized therapy for prostate cancer. Front Oncol (2012) 0.90
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci (2013) 0.89
ProstaScint(R) Scan: Contemporary Use in Clinical Practice. Rev Urol (2004) 0.86
Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev (2012) 0.83
Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy. Radiat Oncol (2007) 0.83
Translational Molecular Imaging of Prostate Cancer. Curr Radiol Rep (2013) 0.82
Is 11C-choline the most appropriate tracer for prostate cancer? Against. Eur J Nucl Med Mol Imaging (2004) 0.81
The emergence of radioimmunoscintigraphy for prostate cancer. Rev Urol (2006) 0.80
The prognostic significance of indium-111-capromab penetide. J Clin Oncol (2004) 0.76
Is 11C-choline the most appropriate tracer for prostate cancer? For. Eur J Nucl Med Mol Imaging (2004) 0.76
The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients. Clin Med Res (2007) 0.75
Molecular imaging of urogenital diseases. Semin Nucl Med (2014) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Accessing antiretroviral therapy following release from prison. JAMA (2009) 5.45
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol (2002) 4.13
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys (2002) 4.01
Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature (2006) 4.00
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. Biometrics (2011) 3.38
131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med (2005) 3.38
Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation (2005) 3.33
Subgroup identification from randomized clinical trial data. Stat Med (2011) 3.22
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. J Nucl Med (2003) 3.15
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med (2004) 3.00
Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer (2008) 2.98
Estimation of α/β for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys (2011) 2.96
Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol (2005) 2.84
Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med (2003) 2.61
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res (2007) 2.60
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 2.59
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
"USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. J Nucl Med (2003) 2.45
National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med (2008) 2.43
Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis (2007) 2.42
Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol (2004) 2.42
Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. Biostatistics (2009) 2.38
Ectopic expression of the sodium-iodide symporter enables imaging of transplanted cardiac stem cells in vivo by single-photon emission computed tomography or positron emission tomography. J Am Coll Cardiol (2008) 2.33
Urinary tract abnormalities: initial experience with multi-detector row CT urography. Radiology (2002) 2.23
Bladder cancer in 2010: how far have we come? CA Cancer J Clin (2010) 2.21
Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol (2006) 2.20
Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol (2009) 2.20
Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res (2007) 2.14
Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology (2011) 2.06
Semiparametric modeling of longitudinal measurements and time-to-event data--a two-stage regression calibration approach. Biometrics (2008) 2.05
Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer (2007) 2.02
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys (2009) 2.01
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol (2004) 2.00
A video game improves behavioral outcomes in adolescents and young adults with cancer: a randomized trial. Pediatrics (2008) 1.98
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med (2011) 1.95
Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med (2003) 1.95
The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2003) 1.93
Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol (2003) 1.92
Delays in diagnosis and bladder cancer mortality. Cancer (2010) 1.92
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
The association of body mass index and prostate-specific antigen in a population-based study. Cancer (2005) 1.85
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol (2003) 1.83
Clinically significant incidental findings on the unenhanced CT portion of PET/CT studies: frequency in 250 patients. J Nucl Med (2005) 1.83
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys (2005) 1.83
Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer. J Urol (2011) 1.79
18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. J Nucl Med (2007) 1.79
Establishment of a urological surgery quality collaborative. J Urol (2010) 1.75
Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med (2007) 1.73
Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med (2005) 1.72
Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol (2005) 1.71
CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med (2010) 1.70
Development and evaluation of a study design typology for human research. AMIA Annu Symp Proc (2009) 1.70
A bayesian approach to surrogacy assessment using principal stratification in clinical trials. Biometrics (2009) 1.69
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
On the detection and refinement of transcription factor binding sites using ChIP-Seq data. Nucleic Acids Res (2010) 1.67
The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol (2008) 1.66
Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med (2003) 1.64
Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. Int J Radiat Oncol Biol Phys (2008) 1.63
Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A (2004) 1.63
Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol (2005) 1.63
Impact of surgical volume on mortality and length of stay after nephrectomy. Urology (2004) 1.62
Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med (2012) 1.62
Prevalence of misregistration between SPECT and CT for attenuation-corrected myocardial perfusion SPECT. J Nucl Cardiol (2007) 1.62
Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology (2005) 1.61
Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol (2002) 1.59
A measure of the proportion of treatment effect explained by a surrogate marker. Biometrics (2002) 1.59
The human studies database project: federating human studies design data using the ontology of clinical research. AMIA Jt Summits Transl Sci Proc (2010) 1.58
Comparison of uptake of multiple clinical radiotracers into brown adipose tissue under cold-stimulated and nonstimulated conditions. J Nucl Med (2007) 1.56
Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. J Urol (2009) 1.55
Understanding bladder cancer death: tumor biology versus physician practice. Cancer (2009) 1.55
Intraoperative nerve stimulation with measurement of urethral sphincter pressure changes during radical retropubic prostatectomy: a feasibility study. J Urol (2003) 1.55
Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med (2009) 1.54
Survival analysis using auxiliary variables via non-parametric multiple imputation. Stat Med (2006) 1.53
18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med (2009) 1.53
A semi-parametric accelerated failure time cure model. Stat Med (2002) 1.53